Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach
暂无分享,去创建一个
[1] C. Guttmann,et al. Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[2] F. Barkhof,et al. Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.
[3] J L Ostuni,et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis , 2001, Multiple sclerosis.
[4] R. Gold,et al. Iron particle-enhanced visualization of inflammatory central nervous system lesions by high resolution: preliminary data in an animal model. , 2006, AJNR. American journal of neuroradiology.
[5] Frederik Barkhof,et al. Grey matter pathology in multiple sclerosis , 2008, The Lancet Neurology.
[6] David H. Miller,et al. The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis , 2002, Journal of Neurology.
[7] Frederik Barkhof,et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. , 2008, Brain : a journal of neurology.
[8] J. Geurts. Is progressive multiple sclerosis a gray matter disease? , 2008, Annals of neurology.
[9] M. Rovaris,et al. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. , 2005, Archives of neurology.
[10] Roland Martin,et al. Therapeutic Potential of Phosphodiesterase-4 and -3 Inhibitors in Th1-Mediated Autoimmune Diseases , 2000, The Journal of Immunology.
[11] Rohit Bakshi,et al. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. , 2004, Archives of neurology.
[12] F. Barkhof,et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.
[13] Hans Lassmann,et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.
[14] K. Selmaj,et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. , 2008, The New England journal of medicine.
[15] H. Waldmann,et al. The window of therapeutic opportunity in multiple sclerosis , 2005, Journal of Neurology.
[16] G. Comi,et al. Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging. , 1999, Magnetic resonance imaging.
[17] G. Stoll,et al. Gadofluorine M enhancement allows more sensitive detection of inflammatory CNS lesions than T2-w imaging: a quantitative MRI study. , 2008, Brain : a journal of neurology.
[18] D. Knol,et al. 1 Persistent T 1 Hypointensity as an MRI Marker for Treatment Ef Þ cacy in Multiple Sclerosis , 2010 .
[19] H. McFarland,et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions , 1993, Annals of neurology.
[20] David H. Miller,et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain , 2004, Annals of neurology.
[21] N. Richert,et al. Magnetization transfer imaging to monitor clinical trials in multiple sclerosis. , 1999, Neurology.
[22] Kyle C. Kern,et al. Regional hippocampal atrophy in multiple sclerosis. , 2008, Brain : a journal of neurology.
[23] Frederik Barkhof,et al. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. , 2007, Archives of neurology.
[24] F. Barkhof,et al. A three-year, multi-parametric MRI study in patients at presentation with CIS , 2008, Journal of Neurology.
[25] A. Thompson,et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis , 2009, Neurology.
[26] T. Waldmann,et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. , 2009, Archives of neurology.
[27] Ludwig Kappos,et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis , 1999, The Lancet.
[28] J. Taubenberger,et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.
[29] Yunyun Duan,et al. Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis. , 2008, European journal of radiology.
[30] F. Barkhof,et al. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. , 1993, Brain : a journal of neurology.
[31] P. Narayana,et al. Improved Identification of Intracortical Lesions in Multiple Sclerosis with Phase-Sensitive Inversion Recovery in Combination with Fast Double Inversion Recovery MR Imaging , 2007, American Journal of Neuroradiology.
[32] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[33] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[34] O. Kantarci,et al. Gray Matter Atrophy Is Related to Long-Term Disability in Multiple Sclerosis , 2009 .
[35] M Filippi,et al. Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis , 1998, Annals of neurology.
[36] A. Thompson,et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.
[37] I. Allen,et al. Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis (MS). , 1981, Acta neuropathologica. Supplementum.
[38] N. Patronas,et al. Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history , 1991, Annals of neurology.
[39] D. Miller,et al. Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses , 2008, Multiple sclerosis.
[40] R. Rudick,et al. Gray matter atrophy in multiple sclerosis: A longitudinal study , 2008, Annals of neurology.
[41] T. Waldmann,et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[42] J A Frank,et al. Time series for modelling counts from a relapsing-remitting disease: application to modelling disease activity in multiple sclerosis. , 1994, Statistics in medicine.
[43] Anthony Traboulsee,et al. Complementary information from multi-exponential T 2 relaxation and diffusion tensor imaging reveals differences between multiple sclerosis lesions , 2008, NeuroImage.
[44] J. Frank,et al. The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis , 1995, Annals of neurology.
[45] J. Wolinsky,et al. 3D MPRAGE improves classification of cortical lesions in multiple sclerosis , 2008, Multiple sclerosis.
[46] M W Weiner,et al. A serial study of new MS lesions and the white matter from which they arise , 1998, Neurology.
[47] M. Horsfield,et al. A Magnetization Transfer MRI Study of Deep Gray Matter Involvement in Multiple Sclerosis , 2006, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[48] James M Provenzale,et al. Multiple sclerosis: diffusion tensor MR imaging for evaluation of normal-appearing white matter. , 2002, Radiology.
[49] F. Barkhof,et al. Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T. , 1992, AJNR. American journal of neuroradiology.
[50] G. Comi,et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.
[51] À. Rovira,et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.
[52] F Barkhof,et al. The role of MRI as a surrogate outcome measure in multiple sclerosis , 2002, Multiple sclerosis.
[53] A. Compston,et al. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench , 2004, Clinical Neurology and Neurosurgery.
[54] C H Polman,et al. MR spectroscopic evidence for glial increase but not for neuro‐axonal damage in MS normal‐appearing white matter , 2005, Magnetic resonance in medicine.
[55] Roland Martin,et al. Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.
[56] J. Duyn,et al. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. , 1998, AJNR. American journal of neuroradiology.
[57] J A Frank,et al. Serial contrast‐enhanced magnetic resonance imaging in patients with early relapsing–remitting multiple sclerosis: Implications for treatment trials , 1994, Annals of neurology.
[58] Neal Jeffries,et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. , 2003, Brain : a journal of neurology.
[59] H. Merkle,et al. Multisequence-imaging protocols to detect cortical lesions of patients with multiple sclerosis: Observations from a post-mortem 3 Tesla imaging study , 2009, Journal of the Neurological Sciences.
[60] Frederik Barkhof,et al. Regional DTI differences in multiple sclerosis patients , 2009, NeuroImage.
[61] G. Barker,et al. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis , 1999, Neurology.
[62] J. Duyn,et al. Tissue-Specific Imaging Is a Robust Methodology to Differentiate In Vivo T1 Black Holes with Advanced Multiple Sclerosis–Induced Damage , 2009, American Journal of Neuroradiology.
[63] Gareth J. Barker,et al. Diffusion tensor imaging of post mortem multiple sclerosis brain , 2007, NeuroImage.
[64] A. Thompson,et al. The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results , 2001, Multiple sclerosis.
[65] B. Trapp,et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.